Genmab (GMAB)'s Future Potential Underappreciated by Market [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
in 2025, with returns driven more by stock-specific research rather than post-pandemic valuation rebounds. A copy of the letter can be downloaded here . The letter attributes performance to disciplined bottom-up investing and improved execution across several portfolio holdings. It also notes that rising global government debt supports the case for equities as core real assets, with non-US markets offering especially attractive valuations. Orbis suggests the long period of US market dominance may be starting to shift and remains focused on buying fundamentally undervalued businesses where mispricing can correct over time. Genmab A/S (NASDAQ: GMAB ) is a biotechnology company specializing in antibody-based therapies, with a strong oncology portfolio and multiple high-value partnerships driving long-term growth. In Orbis International Equity's Q4 2025 investor letter, Genmab A/S (NASDAQ:GMAB) is highlighted as the fund's largest position, benefiting from what Orbis sees as deep underv
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]Yahoo! Finance
- Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.MarketBeat
- Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]Yahoo! Finance
- Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]Seeking Alpha